Gender differences in <scp>Egyptian</scp> patients hospitalized with heart failure: insights from the <scp>European Society of Cardiology Heart Failure Long‐Term Registry</scp>

Hassanein, Mahmoud; Abdelhamid, Magdy; Ibrahim, Bassem; Sobhy, Mohamed; Nasr, Gamela; Aboleineen, Mohamed Wafaie; Reda, Ashraf; Farag, Nabil; El-Shazly, Atef M; Abdeldayem, T K; Elmesseiry, Fatma; Boshra, Hesham; Sobhy, Hesham; Elbahry, Atef; Youssef, Amr Ahmed Aly; Ashmawy, Medhat Mohamed; Abdel‐Moneim, Ahmed S.; Saleh, Ayman; Elrakshy, Yahya; Ebeid, Hamdy

doi:10.1002/ehf2.12347

Cited by 17 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study indicated one counterintuitive result that women bore a higher overall incidence of CHF than men did. However, previous investigations of sex-specific epidemiology of CHF have demonstrated that women with atrial fibrillation have a higher incidence of heart failure with preserved ejection fraction, especially in very old age compared with men 44–46. In this study, CVF was associated with an increased risk of CHF, and the results remained statistically significant across various age and sex strata, as well as with or without comorbidities.…”

Section: Discussionsupporting

confidence: 49%

Risk of aortic dissection, congestive heart failure, pneumonia and acute respiratory distress syndrome in patients with clinical vertebral fracture: a nationwide population-based cohort study in Taiwan

et al. 2019

View full text Add to dashboard Cite

ObjectiveStudies on the association between clinical vertebral fractures (CVFs) and the subsequent risk of cardiopulmonary diseases, including aortic dissection (AD), congestive heart failure (CHF), pneumonia and acute respiratory distress syndrome (ARDS) are scarce. Therefore, we used the National Health Insurance Research Database to investigate whether patients with CVF have a heightened risk of subsequent AD, CHF, pneumonia and ARDS.DesignThe National Health Insurance Research Database was used to investigate whether patients with CVFs have an increased risk of subsequent AD, CHF, pneumonia and ARDS.ParticipantsThis cohort study comprised patients aged ≥18 years with a diagnosis of CVF and were hospitalised at any point during 2000–2010 (n=1 08 935). Each CVF patient was frequency-matched to a no-CVF hospitalised patients based on age, sex, index year and comorbidities (n=1 08 935). The Cox proportional hazard regressions model was used to estimate the adjusted effect of CVF on AD, CHF, pneumonia and ARDS risk.ResultsThe overall incidence of AD, CHF, pneumonia and ARDS was higher in the CVF group than in the no-CVF group (4.85 vs 3.99, 119.1 vs 89.6, 283.3 vs 183.5 and 9.18 vs 4.18/10 000 person-years, respectively). After adjustment for age, sex, comorbidities and Charlson comorbidity index score, patients with CVF had a 1.23-fold higher risk of AD (95% CI=1.03–1.45), 1.35-fold higher risk of CHF (95% CI=1.30–1.40), 1.57-fold higher risk of pneumonia (95% CI=1.54–1.61) and 2.21-fold higher risk of ARDS (95% CI=1.91–2.57) than did those without CVF. Patients with cervical CVF and SCI were more likely to develop pneumonia and ARDS.ConclusionsOur study demonstrates that CVFs are associated with an increased risk of subsequent cardiopulmonary diseases. Future investigations are encouraged to delineate the mechanisms underlying this association.

show abstract

Section: Discussionsupporting

confidence: 49%

Risk of aortic dissection, congestive heart failure, pneumonia and acute respiratory distress syndrome in patients with clinical vertebral fracture: a nationwide population-based cohort study in Taiwan

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Anemia was highly prevalent across regions, especially in Upper Egypt where it was seen in almost 80% of patients. Hassanein et al have reported that anemia is particularly prevalent among Egyptian women with HF as compared to men, 35.4% versus 18.9%, respectively [4]. In a systematic review and meta-analysis by Groenveld et al [10], anemia was associated with an increased risk of mortality in both systolic and diastolic HF.…”

Section: Discussionmentioning

confidence: 98%

“…The European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) Registry, in which Egypt participated as a member country, provided the first representative data on HF patients in the country [3]. Studies comparing the cohort of heart failure (HF) patients in Egypt to the European cohorts, as well as gender differences of HF patients within Egypt, have been published [4,5]. However, no study to date has compared the characteristics and outcomes of HF patients across the different regions of Egypt.…”

Section: Introductionmentioning

confidence: 99%

Demographics, clinical characteristics, and outcomes among hospitalized heart failure patients across different regions of Egypt

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Regional level data on hospitalized heart failure (HHF) patients in Egypt is scarce. The aim of this study was to compare the demographics, clinical characteristics, and outcomes of HHF patients from four distinct geographical regions of Egypt. Results: Study participants were part of the European Society of Cardiology Heart Failure Long Term (ESC-HF-LT) Registry, which enrolled patients from April 2011 to February 2014. A total of 1661 HHF patients from Egypt were enrolled, of whom 1645 were eligible for analysis: 914 from Alexandria, 249 from Cairo, 409 from the Delta region, and 73 from Upper Egypt. The mean age ranged from 52.2 to 62.8 years and differed significantly between the 4 groups (P < 0.01). Females represented one-third of the cohort (P = 0.5 between groups). The prevalence of obesity, diabetes, and hypertension also varied significantly across the groups (P < 0.01). The most common etiology of heart failure (HF) was ischemic heart disease. HF with reduced systolic function was the leading type of HF in the 4 groups (P = 0.6). The most common valvular abnormality in all regions was mitral regurgitation. For patients with prior history of HF, community-acquired infection was the most common reason for a HF exacerbation in all 4 groups. In-hospital mortality ranged from 2.9 to 7.7% in the 4 groups (P = 0.06). Only Alexandria and Delta groups provided reliable 1-year follow-up data, given low patient retention in Cairo and Upper Egypt groups. At one-year, 32% of patients from Alexandria compared to 22.6% from Delta were re-hospitalized for HF (P < 0.01). Mortality at 1 year was also significantly higher in Alexandria compared to Delta, 31.8 vs 13.2% respectively (P < 0.01). Conclusions: HHF patients from different geographic regions of Egypt differed significantly in their demographics, clinical characteristics, and outcomes. Those differences underscore the importance of region-specific HF prevention and management strategies.

show abstract

“…These studies could provide better understanding of the effect of the antidiabetes drugs on HF in patients with or without T2DM, and could potentiate to broaden the use of these drugs beyond their conventional therapeutic use. Moreover, many co-morbidities other than T2DM and prediabetes such as cachexia and muscle wasting, anaemia and iron deficiency, chronic obstructive pulmonary disease and sleep apnoea are also important in managing HF patients [44][45][46][47][48][49][50].…”

Section: Cardiovascular Outcomes With Sglt-2 Inhibitorsmentioning

confidence: 99%

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents

Anker¹

2020

Diabetes mellitus

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM) is a recognised risk factor for several cardiovascular (CV) conditions including heart failure (HF). Findings that reflect CV risk associated with T2DM medications have led to regulatory requirement of conducting CV outcome trials (CVOTs) for new antidiabetes drugs. Over the years, several CVOTs using different glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors have reported neutral or improved CV risks or hospitalisation for HF. However, these studies included only a small proportion of the patients with baseline HF thus limiting the available evidence. Ongoing trials such as EMPEROR programme and DAPA-HF in large patient populations with chronic HF could potentially broaden the use of these drugs beyond their conventional therapeutic indication.

show abstract

Gender differences in Egyptian patients hospitalized with heart failure: insights from the European Society of Cardiology Heart Failure Long‐Term Registry

Abstract: Men and women with AHF differ significantly in baseline clinical characteristics and management but not in adverse outcomes. These findings emphasize the importance of individualized management and need for more comprehensive recruitment of women in clinical trials.

Cited by 17 publications

References 35 publications

Risk of aortic dissection, congestive heart failure, pneumonia and acute respiratory distress syndrome in patients with clinical vertebral fracture: a nationwide population-based cohort study in Taiwan

Risk of aortic dissection, congestive heart failure, pneumonia and acute respiratory distress syndrome in patients with clinical vertebral fracture: a nationwide population-based cohort study in Taiwan

Demographics, clinical characteristics, and outcomes among hospitalized heart failure patients across different regions of Egypt

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents

Contact Info

Product

Resources

About